Immune System Key

Drug development for malignant and autoimmune diseases.

Health Tech & Life Sciences
Active
Seed Jerusalem, Israel Founded 2005
Last updated 2026-07-26
Total raised
$2.5M
Last: Grant 2017-01
Stage
Seed
Founded
2005
Headcount
2
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Immune System Key (ISK) Ltd. is a privately held, clinical-stage biotechnology company focused on the discovery and development of innovative treatments for malignant and autoimmune diseases. The company's therapeutic assets are based on novel human secreted peptides discovered by its founders. ISK's lead compound, Nerofe™, is a peptide derivative being explored for various oncology indications, including Acute Myeloid Leukemia (AML), pancreatic cancer, and metastatic colorectal cancer, as well as Alzheimer's disease. ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS.

Funding history · 3 rounds · $2.5M total

2015-04
Grant $800K
2015-01
Grant $1.0M
1969-12
Grant $700K

Headcount over time

From 2 (2018-09) to 2 (2025-10) · +0 (+0%) · 5 points · source: Finder history + radar grounding
70 2018-09 2025-10

Q&A

What is Immune System Key's primary focus in drug development?
Immune System Key (ISK) is focused on the discovery and development of treatments for malignant cancers and autoimmune diseases, specifically targeting acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer.
What is Immune System Key's lead compound and its key features?
Immune System Key's lead compound is Nerofe, which aims to inhibit three biological processes supporting cancer progression. Phase-1 testing showed a strong anti-angiogenic effect and activation of anticancer immune response. Nerofe has been granted orphan status by the FDA for AML treatment.
How many employees does Immune System Key currently have?
Immune System Key has 1-10 employees.
Who are the co-founders of Immune System Key?
The co-founders of Immune System Key are Dr. Yoram Devary, who serves as Co-founder, Chairman & CTO, and Prof. Uziel Sandler, who is Co-founder, Vice-Chairman & CEO.
What is the total amount of funding Immune System Key has raised?
Immune System Key has raised a total of $3,700,000.
When was Immune System Key founded?
Immune System Key was founded in February 1992.
Has Immune System Key received any grants from the Israel Innovation Authority?
Yes, Immune System Key received grants from the Israel Innovation Authority in January 2016 and January 2017.
What is the product stage of Immune System Key's developments?
Immune System Key's developments are in the clinical trial stage.

Team · 2

Uziel Sandler
Founder · Co-Founder
Yoram Devary
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProviders
Business model
B2BB2C

Highlights

1 Patents

Tags

cancerpharmaceuticalsoncologybiotechnologydrug-discoverypeptidestreatmentsautoimmune-diseaseshealthcare-providershospitals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteimmunesk.com
LinkedInlinkedin.com/company/2619379

Identifiers & details

Legal nameImmune System Key Ltd.
Former namesThymuFight
Founded2005
Employees (exact)2

Radar intelligence

Patents

EPO9

Web history (Wayback)

Domainimmunesk.com

Certificate / subdomain footprint

Subdomains3

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513754820
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2005-11-24
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2023
Active charges / liens0
Registry events3 — people (1), violation (1), shares_capital (1)
Registered addressרוזנבלט 318 ירושלים

Recent registry events

DateEvent
2025-10-30עדכון בעלי תפקידים
2026-06-25עדכון הפרה
2025-12-14העברת מניות